About
Technology
Issues
FAQ
Links
Official Page
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.